Kevin Cruz-Mora

Dr. Kevin Cruz-Mora


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.

14 October 2025 in Emergency Care and Medicine
Verified
Journal Article
Open access
PDF file
AMAbigail Fallas Mora
Abigail Fallas Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
JDJosé M Díaz-Madriz
José M Díaz-Madriz
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background/Objectives: In-hospital cardiac arrest (IHCA) remains a critical event with high mortality, requiring coordinated multidisciplinary response. Return of spontaneous circulation (ROSC) and hospital discharge rates are key quality indicators in resuscitation efforts. In Costa Rica, there is limited published data on team performance, protocol adherence, and the pharmacist’s role in code blue events, despite similar evidence gaps across Latin America. This study aimed to evaluate clinical outcomes and operational performance of in-hospital cardiac arrest events at a Costa Rica hospital. Methods: This retrospective cohort study included 77 adult patients who experienced IHCA at Clínica Bíblica between 2020 and 2024. Data collection was conducted between February and May 2025 from electronic medical records and code blue activation logs. Clinical variables, comorbidities, pharmacologic interventions, and outcomes were analyzed. Predictive models (Charlson Comorbidity Index [CCI], IHCA-ROSC, RISQ-PATH) and Kaplan–Meier survival analysis were applied. Results: ROSC was achieved in 55.8% of patients, and 21% were discharged alive. Asystole was the predominant initial rhythm (76.6%), and comorbidities such as renal disease and myocardial infarction were most frequent. A higher comorbidity burden was significantly associated with lower discharge rates (p = 0.032). Despite 98.7% of patients being classified as low probability for ROSC by the IHCA-ROSC model, observed outcomes exceeded expectations (predicted: 5.53% vs. actual: 55.84%; p < 0.000001). The code team adhered to institutional protocols in 100% of cases, with clinical pharmacists playing a key role in documentation and medication tracking. Conclusions: Structured multidisciplinary response was associated with ROSC rates notably higher than predicted by validated models. Opportunities for improvement include post-event laboratory testing, pharmacist-led documentation, and therapeutic hypothermia in shockable rhythms.

20 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAbigail Fallas Mora
Abigail Fallas Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
JDJosé M Díaz-Madriz
José M Díaz-Madriz
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background/Objectives:In-hospital cardiac arrest (IHCA) remains a critical event with high mortality, requiring coordinated multidisciplinary response. Return of spontaneous circulation (ROSC) and hospital discharge rates are key quality indicators in resuscitation efforts. In Latin America, there is limited data on team performance, protocol adherence, and the pharmacist’s role in code blue events. This study aimed to evaluate clinical outcomes and operational performance of code blue events at a Latin American hospital.Methods:This retrospective cohort study included 77 adult patients who experienced IHCA at Hospital Clínica Bíblica between 2020 and 2024. Data collection was conducted between February and May 2025 from electronic medical records and code blue activation logs. Clinical variables, comorbidities, pharmacologic interventions, and outcomes were analyzed. Predictive models (Charlson Comorbidity Index [CCI], IHCA-ROSC, RISQ-PATH) and Kaplan–Meier survival analysis were applied.Results: ROSC was achieved in 55.8% of patients, and 21% were discharged alive. Asystole was the predominant initial rhythm (76.6%), and comorbidities such as renal disease and myocardial infarction were most frequent. A higher comorbidity burden was significantly associated with lower discharge rates (p = 0.032). Despite 98.7% of patients being classified as low probability for ROSC by the IHCA-ROSC model, observed outcomes exceeded expectations (predicted: 5.53% vs. actual: 55.84%; p < 0.000001). The code team adhered to institutional protocols in 100% of cases, with clinical pharmacists playing a key role in documentation and medication tracking.Conclusions:Structured multidisciplinary response was associated with ROSC rates notably higher than predicted by validated models. Opportunities for improvement include post-event laboratory testing, pharmacist-led documentation, and therapeutic hypothermia in shockable rhythms.

6 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.

1 October 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
JMJeaustin Arón Mora
Jeaustin Arón Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
SCSofía Segura Cano
Sofía Segura Cano
YQYajaira Quesada
Yajaira Quesada
JGJose Alberto Gatgens Gómez
Jose Alberto Gatgens Gómez
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background: Pharmacist involvement in immunization has expanded as a strategy to improve access to vaccines. In Costa Rica, private community pharmacies operate under a regulatory framework for vaccination services, yet evidence on private-market vaccine dispensing remains limited. The aim of this study was to characterize vaccine dispensing through private community pharmacies in Costa Rica by dispensed doses, economic value, vaccine category, and provincial distribution, comparing MAT February 2025 and MAT February 2026. Methods: A descriptive, retrospective, national study was conducted using an aggregated secondary IQVIA database of the Costa Rican private pharmaceutical market. Dispensed doses, economic value in USD, percentage variation, and share by vaccine category and province were analyzed; no individual patient, professional, establishment, or nominal vaccination records were used. Results: Dispensed doses increased from 162,664 to 217,387 (+33.6%), while economic value increased from USD 8,700,809 to USD 13,416,717 (+54.2%). Influenza accounted for the highest dispensing volume in MAT February 2026 (87,064 doses). Yellow fever showed the largest between-period increase, from 22,281 to 70,133 doses and from USD 2.7 million to USD 7.0 million. HPV ranked second in economic value (USD 3.6 million). San José accounted for 63.0% of dispensed doses and 52.9% of national private-market economic value. Conclusions: Private-market vaccine dispensing through Costa Rican community pharmacies was higher in MAT February 2026 than in MAT February 2025 in both dispensed doses and economic value, driven primarily by yellow fever. Influenza accounted for the highest dispensing volume, while HPV retained substantial economic weight. These findings characterize vaccine dispensing through the private community pharmacy market but do not establish vaccine administration, vaccination coverage, or clinical or epidemiological outcomes.

3 October 2026 in Psychoactives
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
KCKevin Cruz-Mora
Kevin Cruz-Mora
RGRicardo Millán González
Ricardo Millán González
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.